Alectinib surpasses crizotinib for untreated ALK-positive NSCLC
- PMID: 28625556
- DOI: 10.1016/S1470-2045(17)30482-5
Alectinib surpasses crizotinib for untreated ALK-positive NSCLC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
